Neumirna Therapeutics (‘Neumirna’), an RNA-focused biotech company developing next-generation therapeutics for neurological disorders, is pleased to announce the firstclosing of its Series A funding round at €20M. The investment was co-led by new investors, AngeliniVentures and Invivo Partners, with significant participation from Neumirna’s seed investor, Innovestor’s Life Science Fund and other investors.
“This funding milestone is a testament to the groundbreaking potential of our RNA-based platform and our lead development candidate, NMT.001”. We are thrilled to have the support of leading international investors, who share our vision of addressing the unmet needs of patients living with neurological disorders. This funding is essential to bring NMT.001 to clinical trials and advance our pipeline.” – Professor Janine Erler, CEO of Neumirna Therapeutics.
Neumirna was founded with the mission to revolutionize the treatment paradigms for challenging neurological conditions, and is at the forefront of RNA therapeutics, harnessing the power of microRNAs(miRNAs) to provide disease-modifying drugs. The company's pioneering drug discovery platform enables the development of RNA therapies targeting previously intractable conditions, such as drug-resistant epilepsy (DRE) and Parkinson’s disease (PD).
With the new funding, Neumirna is poised to expand its research and development, scale its platform, and drive NMT.001 through the next key stages of development. This funding round marks a pivotal moment for Neumirna as it advances toward its goal of delivering life-changing therapies to patients in need.
“As co-lead investors, we are proud to support Neumirna in its mission to harness the potential of RNA therapies to tackle epilepsy and other complex neurological disorders,” said Thomas Thestrup, Senior Principal at Angelini Ventures.
“By leveraging microRNA-targeted drugs to address the underlying causes of diseases like epilepsy and Parkinson’s disease, Neumirna is breaking new ground in the field. With our strong focus on brain disorders and a commitment to advancing innovative treatments for epilepsy, we are excited to collaborate with Neumirna’s management team on this journey to develop transformative solutions for patients worldwide”.
"Investing in Neumirna represents a unique opportunity to support a pioneering company in leveraging RNA technology to treat neurological diseases" said Luis Pareras, Managing Partner at InvivoPartners. "As a neurosurgeon, I am deeply impressed by the innovative approach and the results ofNMT.001. The possibility of offering a transformative solution for patients with refractory, drug-resistant epilepsy, a devastating condition, is tremendously encouraging”.
Both Luis Pareras and Thomas Thestrup have been appointed to the Board of Directors, joining Milla Koistinaho, from Innovestor’s Life Science Fund, and Dr. Henrik Klitgaard, Scientific co-Founder of Neumirna Therapeutics.
About Neumirna Therepeutics
Neumirna Therapeutics, based in Copenhagen, Denmark, is a biotechnology company focused on developing RNA-based therapies to treat neurological diseases. Founded in 2020 by Dr. Henrik Klitgaard, Prof. Sakari Kauppinen and Lars Hellerung Christiansen, Neumirna is dedicated to transforming patients' lives through the modulation of microRNAs with therapies that have the potential to address the root cause of diseases. Neumirna was seed financed by Sunstone Life Science Ventures, Innovestor, and private investors, and is supported by the Innovation Fund Denmark, as well as the Michael J Fox Foundation and a Eurostars grant for the Parkinson’s program.
About Angelini Ventures
Angelini Ventures, the venture capital arm of Angelini Industries, is an early-stage investment firm focused on accelerating disruptive innovations and trends in BioTech and Digital Health. The firm will invest €300 million across a global portfolio led by investment professionals and advisors in Europe, North America, and Asia. Angelini Ventures has deep domain expertise and leverages a global team, advisors, and strategic partners to help entrepreneurs scale their businesses into transformative category-leading companies.To date, Angelini Ventures has invested €80 million into 15 companies (five of which were created with Angelini Lumira Biosciences Fund) covering a range of therapeutic areas and modalities, including Cour Pharmaceuticals, Noctrix Health, Nouscom, Avation Medical, Pretzel Therapeutics, Cadence Neuroscience and Freya Biosciences.
About Invivo Partners
Invivo Partners is a venture capital firm specializing in early-stage life sciences companies. It is managed by Luis Pareras, Albert Ferrer, and Laura Rodríguez, with investments in 15 companies and three fund sunder management. The firm recently announced its third fund, targeting €100 million for investments in early-stage life science companies at the intersection of advanced therapies, synthetic biology, and artificial intelligence. Invivo Ventures III has a majority of private investors with the support of a number of institutional investors such as the European Investment Fund (EIF), Fond-ICO Next Tech, the CatalanFinance Institute and the Barcelona City Council.
About Innovestor
Innovestor is a Finnish investment company focusing on venture capital and real estate. The firm currently manages six VC funds with total capital of over €250 million. Consisting of over 100 growth companies across multiple sectors of technology, life science and health, it represents one of the largest private venture-backed portfolios in the Nordics.
